Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma

pharmafile | November 8, 2019 | News story | Medical Communications, Research and Development |  Ninlaro, Takeda, multiple myeloma, pharma 

Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line maintenance treatment of multiple myeloma in adult patients not treated with stem cell transplantation.

In a Phase 3 study incorporating 706 multiple myeloma patients who had completed 6-12 months of initial therapy and achieved a partial response or better, Ninlaro demonstrated a “statistically significant” improvement in progression free survival compared to placebo, meeting its primary endpoint.

The safety profile of the drug was also found to be in line with previous data.

“We are very encouraged by the results of the TOURMALINE-MM4 trial and continue our forward momentum in developing maintenance options for multiple myeloma patients. Importantly, this is the third positive Phase 3 readout from the TOURMALINE clinical trial programme,” commented Dr Phil Rowlands, Head of the Oncology Therapeutic Area Unit at Takeda. “We remain committed to bringing this convenient and well-tolerated treatment option to patients.”

Advertisement

The company confirmed it would unveil the full results from the study at an upcoming medical meeting.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Von Willebrand disease – increasing awareness and access to vital care

Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

The Gateway to Local Adoption Series

Latest content